» Articles » PMID: 22666368

MALDI-TOF MS Enables the Rapid Identification of the Major Molecular Types Within the Cryptococcus Neoformans/C. Gattii Species Complex

Overview
Journal PLoS One
Date 2012 Jun 6
PMID 22666368
Citations 50
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The Cryptococcus neoformans/C. gattii species complex comprises two sibling species that are divided into eight major molecular types, C. neoformans VNI to VNIV and C. gattii VGI to VGIV. These genotypes differ in host range, epidemiology, virulence, antifungal susceptibility and geographic distribution. The currently used phenotypic and molecular identification methods for the species/molecular types are time consuming and expensive. As Matrix-Assisted Laser Desorption Ionization-Time-of-Flight Mass Spectrometry (MALDI-TOF MS) offers an effective alternative for the rapid identification of microorganisms, the objective of this study was to examine its potential for the identification of C. neoformans and C. gattii strains at the intra- and inter-species level.

Methodology: Protein extracts obtained via the formic acid extraction method of 164 C. neoformans/C. gattii isolates, including four inter-species hybrids, were studied.

Results: The obtained mass spectra correctly identified 100% of all studied isolates, grouped each isolate according to the currently recognized species, C. neoformans and C. gattii, and detected potential hybrids. In addition, all isolates were clearly separated according to their major molecular type, generating greater spectral differences among the C. neoformans molecular types than the C. gattii molecular types, most likely reflecting a closer phylogenetic relationship between the latter. The number of colonies used and the incubation length did not affect the results. No spectra were obtained from intact yeast cells. An extended validated spectral library containing spectra of all eight major molecular types was established.

Conclusions: MALDI-TOF MS is a rapid identification tool for the correct recognition of the two currently recognized human pathogenic Cryptococcus species and offers a simple method for the separation of the eight major molecular types and the detection of hybrid strains within this species complex in the clinical laboratory. The obtained mass spectra provide further evidence that the major molecular types warrant variety or even species status.

Citing Articles

Comparative evaluation of sensititre YeastOne and VITEK2 antifungal susceptibility tests with CLSI broth microdilution method of clinical isolates in Taiwan.

Weng T, Wang S, Lo S, Su S, Hsieh M, Tsai P Microbiol Spectr. 2024; 13(2):e0211724.

PMID: 39699241 PMC: 11792495. DOI: 10.1128/spectrum.02117-24.


Determining Potential Link between Environmental and Clinical Isolates of Species Complexes Using Phenotypic and Genotypic Characterisation.

Kebabonye K, Jongman M, Loeto D, Moyo S, Choga W, Kasvosve I Mycobiology. 2024; 51(6):452-462.

PMID: 38179115 PMC: 10763847. DOI: 10.1080/12298093.2023.2272380.


What's New in : From Bench to Bedside and Beyond.

Beardsley J, Dao A, Keighley C, Garnham K, Halliday C, Chen S J Fungi (Basel). 2023; 9(1).

PMID: 36675862 PMC: 9865494. DOI: 10.3390/jof9010041.


Genotypic Diversity and Antifungal Susceptibility of Clinical Isolates of Cryptococcus Gattii Species Complex from Argentina.

Taverna C, Arias B, Firacative C, Vivot M, Szusz W, Vivot W Mycopathologia. 2023; 188(1-2):51-61.

PMID: 36609823 DOI: 10.1007/s11046-022-00705-x.


The Cryptococcus gattii species complex: Unique pathogenic yeasts with understudied virulence mechanisms.

Saidykhan L, Onyishi C, May R PLoS Negl Trop Dis. 2022; 16(12):e0010916.

PMID: 36520688 PMC: 9754292. DOI: 10.1371/journal.pntd.0010916.


References
1.
Viviani M, Esposto M, Cogliati M, Montagna M, Wickes B . Isolation of a Cryptococcus neoformans serotype A MATa strain from the Italian environment. Med Mycol. 2002; 39(5):383-6. DOI: 10.1080/mmy.39.5.383.386. View

2.
Franzot S, Salkin I, Casadevall A . Cryptococcus neoformans var. grubii: separate varietal status for Cryptococcus neoformans serotype A isolates. J Clin Microbiol. 1999; 37(3):838-40. PMC: 84578. DOI: 10.1128/JCM.37.3.838-840.1999. View

3.
Trilles L, Fernandez-Torres B, Lazera M, Wanke B, Guarro J . In vitro antifungal susceptibility of Cryptococcus gattii. J Clin Microbiol. 2004; 42(10):4815-7. PMC: 522305. DOI: 10.1128/JCM.42.10.4815-4817.2004. View

4.
Meyer W, Castaneda A, Jackson S, Huynh M, Castaneda E . Molecular typing of IberoAmerican Cryptococcus neoformans isolates. Emerg Infect Dis. 2003; 9(2):189-95. PMC: 2901947. DOI: 10.3201/eid0902.020246. View

5.
Byrnes 3rd E, Bartlett K, Perfect J, Heitman J . Cryptococcus gattii: an emerging fungal pathogen infecting humans and animals. Microbes Infect. 2011; 13(11):895-907. PMC: 3318971. DOI: 10.1016/j.micinf.2011.05.009. View